EQS-Adhoc: Vitruvia Medical AG: Annual results as of 31.12.2022 and outlook 2023

Vitruvia Medical AG: Annual results as of 31.12.2022 and outlook 2023

Anglikon, June 25, 2023: Vitruvia Medical AG reported net income after taxes of CHF -1,095,349.38 for the year ended December 31, 2022, compared to CHF -8,002,497.53 in the previous year.

On a consolidated basis, Vitruvia Medical AG generated revenues of EUR 1,525,529.-- and operating earnings before interest, taxes, depreciation and amortization (EBITA) of EUR -912,086. Earnings after taxes amount to EUR -1,484,556 compared to the previous year of EUR -8,131,520.00.

Outlook 2023

For the current year, Vitruvia Medical AG and its subsidiary LT technologies GmbH & Co. KG to generate revenues of approximately EUR 1.8 million and earnings (before interest, taxes, depreciation and amortization) of approximately EUR 304,000 (unconsolidated).

On a consolidated basis, Vitruvia Medical AG expects a further improvement in earnings compared to the previous year, which will, however, still be in negative territory.

About Vitruvia Medical AG:

Vitruvia Medical AG is a Swiss investment company focused on the repair, production and trade of medical devices as well as surgical instruments.

Vitruvia thus combines innovative and sustainable solutions for medical-technical progress, customer benefit and economic success.

Vitruvia Medical AG

Markus A. Bertschin

President of the Board of Directors

Kesselackerstrasse 18

CH-5611 Anglikon

kontakt@vitruvia-med.com